Professor Achim Kaufhold, M.D. (49) joins Pharmexa as Executive Vice President,
Chief Scientific Officer (CSO) and Chief Medical Officer (CMO).
Dr Kaufhold has spent more than 12 years in the biotech and pharmaceutical
industry in senior management positions. Prior to starting up his own life
science industry consultancy in 2006, Dr Kaufhold held the position of Chief
Medical Officer & Vice President of Development at Chiron, now part of the
Novartis group, as well as being a member of the executive committee of Chiron
Vaccines. Dr Kaufhold joined Chiron from Berna Biotech, now a Crucell company,
where he was Chief Medical Officer, Head of Research, Product & Business
Development and a member of the executive committee. Before joining Berna, Dr
Kaufhold was Head of the unit responsible for the world-wide development of the
pediatric vaccine portfolio at GlaxoSmithKline.
Dr Achim Kaufhold has had an impressive academic career in the fields of
pediatrics, basic and applied medical microbiology, laboratory medicine and
infectious diseases, both in his native Germany and in the USA. Since 1993 he
has been Professor of Medical Microbiology and Infectious Diseases and a member
of the Faculty of Medicine of the University of Aachen, Germany.
Dr Achim Kaufhold says: “I am excited to be joining Pharmexa's team of seasoned
professionals. I have been impressed with the strength of the technology
platforms and Pharmexa's track record of translating research into product
development. Clearly, Pharmexa is at the forefront of innovation and has
established itself as a leading player in the field of active immunotherapy.
The diversified portfolio of product candidates addresses significant unmet
medical needs. Besides its application in infectious diseases, active
immunotherapy is widely regarded as one of the most promising future treatments
of cancer and other diseases, such as bone disorders or Alzheimers' disease.”
Jakob Schmidt, CEO of Pharmexa says: “As we focus on taking our company to the
next level, Achim will bring to Pharmexa additional operational and strategic
insight in general management, product development and partnership building.
Achim has a strong track record of international research and development
management of novel products, as well as licensing and launches of products
world-wide. We look forward to welcoming Achim to Pharmexa.“
In the newly created position of Executive Vice President, Chief Scientific
Officer and Chief Medical Officer, Dr Achim Kaufhold will report to Pharmexa's
CEO, Jakob Schmidt.
Hørsholm, September 18, 2007
Jakob Schmidt
Chief Executive Officer
Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45
4516 2525
Claude Mikkelsen, Vice President, Corporate Affairs and Communication,
telephone +45 4516 2525 or +45 4060 2558
Note to editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer, serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer and
chronic diseases, as well as serious infectious diseases such as HIV,
influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide
vaccine that has entered phase III trials in pancreatic cancer and phase II
trials in liver cancer, and HIV and hepatitis vaccines in phase I/II.
Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma and
Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs
approximately 105 people and is listed on the Copenhagen Stock Exchange under
the trading symbol PHARMX.
